Tivic Health Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million

Reuters03-26

<a href="https://laohu8.com/S/TIVC">Tivic Health</a> Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million

Tivic published a full-year earnings release reporting operating expenses of USD 7.9 million, up 75.56%.
Net loss before discontinued operations was expected to be USD 7.9 million to USD 8.1 million, up 75.56%.
Net loss was expected to be USD 8.8 million to USD 9.1 million, up 54.39%.
Cash and cash equivalents totaled USD 12.6 million, up more than 5x, with working capital of USD 12.4 million.
Michael K. Handley said the expense increase reflected the addition of a biopharma business to advance Entolimod and added headcount, including 45 employees hired after forming Velocity Bioworks as a CDMO subsidiary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603251605ACCESSWRNAPR_____1151608) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622004918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622004918","market":"fut","top_or_hot":-1,"title":"Tivic Health Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Tivic published a full-year earnings release reporting operating expenses of USD 7.9 million, up 75.56%.\n        </li>\n<li>\n          Net loss before discontinued operations was expected to be USD 7.9 million to USD 8.1 million, up 75.56%.\n        </li>\n<li>\n          Net loss was expected to be USD 8.8 million to USD 9.1 million, up 54.39%.\n        </li>\n<li>\n          Cash and cash equivalents totaled USD 12.6 million, up more than 5x, with working capital of USD 12.4 million.\n        </li>\n<li>\n          Michael <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Handley said the expense increase reflected the addition of a biopharma business to advance Entolimod and added headcount, including 45 employees hired after forming Velocity Bioworks as a CDMO subsidiary.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603251605ACCESSWRNAPR_____1151608) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Tivic published a full-year earnings release reporting operating expenses of USD 7.9 million, up 75.56%.\n        </li>\n<li>\n          Net loss before discontinued operations was expected to be USD 7.9 million to USD 8.1 million, up 75.56%.\n        </li>\n<li>\n          Net loss was expected to be USD 8.8 million to USD 9.1 million, up 54.39%.\n        </li>\n<li>\n          Cash and cash equivalents totaled USD 12.6 million, up more than 5x, with working capital of USD 12.4 million.\n        </li>\n<li>\n          Michael <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Handley said the expense increase reflected the addition of a biopharma business to advance Entolimod and added headcount, including 45 employees hired after forming Velocity Bioworks as a CDMO subsidiary.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603251605ACCESSWRNAPR_____1151608) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLbsbMsz:1","article_id":"2622004918","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622004918","pubTimestamp":1774469200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tivic published a full-year earnings release reporting operating expenses of USD 7.9 million, up 75.56%.Net loss was expected to be USD 8.8 million to USD 9.1 million, up 54.39%.Cash and cash equivalents totaled USD 12.6 million, up more than 5x, with working capital of USD 12.4 million.Michael K. Handley said the expense increase reflected the addition of a biopharma business to advance Entolimod and added headcount, including 45 employees hired after forming Velocity Bioworks as a CDMO subsidiary.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","TIVC":"Tivic Health Systems, Inc."},"translate_title":"Tivic Health Systems 2025财年运营费用增长75.56%至790万美元；净亏损扩大57.89%至900万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIVC":0.9},"content_text":"Tivic Health Systems FY2025 operating expenses jump 75.56% to $7.9 million; net loss widens 57.89% to $9 million\n    \n\n\n          Tivic published a full-year earnings release reporting operating expenses of USD 7.9 million, up 75.56%.\n        \n\n          Net loss before discontinued operations was expected to be USD 7.9 million to USD 8.1 million, up 75.56%.\n        \n\n          Net loss was expected to be USD 8.8 million to USD 9.1 million, up 54.39%.\n        \n\n          Cash and cash equivalents totaled USD 12.6 million, up more than 5x, with working capital of USD 12.4 million.\n        \n\n          Michael K. Handley said the expense increase reflected the addition of a biopharma business to advance Entolimod and added headcount, including 45 employees hired after forming Velocity Bioworks as a CDMO subsidiary.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603251605ACCESSWRNAPR_____1151608) on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622004918","isCrawlerRequest":true}